UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of August 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 8 August 2025,
London UK
GSK Provides Update on US settlement
of CureVac/BioNTech mRNA patent litigation
● CureVac will make an upfront settlement of $370
million to GSK
● GSK
will receive a 1% royalty on future Pfizer / BioNTech US sales of
influenza, COVID-19 and related combination mRNA vaccine
products
GSK plc (LSE/NYSE: GSK) today announces that, in connection with
the mRNA patent settlement reached between CureVac and BioNTech on
7 August 2025, the Company will receive an upfront settlement of
$370 million. GSK will also receive a 1% royalty in respect of US
sales of influenza, COVID-19 and related combination mRNA vaccine
products by BioNTech and Pfizer from the beginning of
2025.
These payments are due to GSK in accordance with the terms of its
existing license agreement with CureVac. Of the upfront settlement
amount, $320m will be in cash. The remainder is attributed to the
value of an amendment to GSK's existing agreement with CureVac,
which includes a significant reduction in royalties to be paid by
GSK on our potential future mRNA influenza, COVID-19 and
influenza/COVID-19 combination products
If the pending acquisition of CureVac by BioNTech successfully
closes, the mRNA patent litigation between CureVac and BioNTech
outside of the US will also be settled. GSK
would then be entitled to an additional $130 million in
cash and 1% royalty payments in respect
of future sales outside of the US by BioNTech and
Pfizer. GSK would also benefit from reduced
milestones and a reduction in royalties payable in respect of
GSK sales of mRNA influenza, COVID-19 and influenza/COVID-19
combination products outside of the US.
The upfront settlement amount
will be recorded as other operating income in GSK's financial
results as an adjusting item in the income statement in the third
quarter of 2025. The 2025 and future royalty income will be
recorded in total and core results in the income
statements.
This settlement does not impact GSK's enforcement of its own
patents against Pfizer and BioNTech in the U.S. and in Europe. GSK
will continue with its litigation against BioNTech and Pfizer for
infringement of GSK's patents.
Simultaneously with the settlement, GSK has entered into a
customary tender and support agreement under which it has agreed to
tender its approximately 16.6 million CureVac shares in the
upcoming offer.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
|
GSK enquiries
|
|
|
|
|
Media:
|
Simon Moore
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
Alison Hunt
|
+1 540 742 3391
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q2 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: August
08, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|